Related Experiment Video
Updated: May 19, 2026
LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism
Published on: April 4, 2016
Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a
Thomas Thiele1, Armin Sablewski, Christina Iuga
1Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Sauerbruchstrasse, Greifswald, Germany. thomas.thiele@uni-greifswald.de
Background:
Pathogen reduction in platelet concentrates (PC) using Amotosalen/UVA-light reduces the risk of transfusion transmitted infections but also decreases the post-transfusion platelet count increment. Little is known about potential platelet lesions caused by Amotosalen/UVA-light, which may reduce therapeutic efficacy of PCs.
Methods:
Platelets from buffy coat (n=15) derived PCs were pooled and split into three equal PC-units. PC-1 was left untreated (control). PC-2 was Amotosalen/UVA treated using the INTERCEPT Blood System(™), PC-3 was gamma irradiated (30 Gy). Samples were prepared one and five days after PC-production for LC-ESI-MS/MS analysis. Proteins displaying treatment-dependent changes in intensity were classified according to Gene Ontology.
Results:
In total, 948 proteins were identified, 721 with ≥2 peptides. At day 1, Amotosalen/UVA-treatment triggered alteration of 23 proteins, and gamma irradiation of 49 proteins (overlap: 11 proteins). Five days storage revealed 58 (Amotosalen/UVA treated), 50 (gamma irradiated), and 36 (controls) changes in the platelet proteome compared to control platelets at day 1. Gene Ontology analysis revealed that many affected proteins were displaying specific catalytic activities and/or protein/nucleic acid binding capacity. We identified platelet endothelial aggregation receptor 1 precursor, chloride intracellular channel protein 4, and protein-tyrosine sulfotransferase 2 as proteins uniquely and consistently altered after treatment and storage of Amotosalen/UVA treated platelets.
Conclusion:
While Amotosalen/UVA-treatment causes less pronounced proteome changes than gamma irradiation at day 1, our data indicate an increase in storage lesions at day 5 caused by this pathogen reduction treatment.
Insights
Amotosalen/UVA-light pathogen reduction in platelet concentrates causes fewer initial proteome changes than gamma irradiation. However, it leads to increased storage lesions in platelets after five days, impacting their therapeutic efficacy.
Area of Science:
- Biochemistry
- Hematology
- Transfusion Medicine
Background:
- Pathogen reduction technologies (PRT) like Amotosalen/UVA-light decrease transfusion-transmitted infections but may affect platelet quality.
- The impact of Amotosalen/UVA-light on platelet lesions and therapeutic efficacy requires further investigation.
Purpose of the Study:
- To investigate the proteomic changes in platelet concentrates (PCs) after Amotosalen/UVA-light treatment and gamma irradiation.
- To compare the effects of Amotosalen/UVA-light and gamma irradiation on platelet storage lesions.
Main Methods:
- Platelet concentrates (PCs) were divided into three groups: untreated (control), Amotosalen/UVA-light treated, and gamma irradiated.
- Proteomic analysis using LC-ESI-MS/MS was performed at one and five days post-production.
- Proteins with treatment-dependent changes were classified using Gene Ontology.
Main Results:
- Amotosalen/UVA-treatment altered 23 proteins at day 1, compared to 49 for gamma irradiation.
- By day 5, Amotosalen/UVA-treated platelets showed 58 proteomic changes versus 50 for gamma-irradiated and 36 for controls.
- Specific proteins like platelet endothelial aggregation receptor 1 precursor were uniquely altered in Amotosalen/UVA-treated platelets.
Conclusions:
- Amotosalen/UVA-light treatment induces fewer immediate proteomic changes than gamma irradiation.
- This pathogen reduction method appears to increase platelet storage lesions by day 5, potentially affecting PC efficacy.
More Related Videos
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019